Emerging Markets Earnings Roundup: Merck And Novo Nordisk (Part 5)
This article was originally published in PharmAsia News
Executive Summary
In this earnings round up, we zoom in on Merck and Novo Nordisk performance in emerging markets for 2012.
You may also be interested in...
With Odanacatib Filing Pushed Back, Merck Reports Flat Top-Line Growth In 2012
Merck’s delay of filing an NDA for its osteoporosis drug odanacatib surprised analysts, but Merck remained mum on its reasoning in a year-end earnings call on Feb. 1.
Once-Weekly Insulin Added To Novo Nordisk’s Clinical Pipeline
Novo Nordisk is evaluating new long-acting and quick-acting insulins in clinical trials as competitive pressure looks set to intensify in 2013 for its market-leading GLP-1 agonist, Victoza.
Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year